Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) PE Ratio (TTM): 12.96 (As of Jul. 21, 2026) — 51% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
94 GF Score
Price ¥38.88
GF Value ¥40.64
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co PE Ratio (TTM)?

Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211 -1.32% 94 PE Ratio (TTM) is 12.96 as of Jul. 21, 2026, which is 51% below its 10-year median of 26.22. GuruFocus rates SHSE:600211 with a GF Score™ of 94/100 and a GF Value™ of ¥40.64 (Fairly Valued). The stock has 2 warning signs investors should review. Among 639 Drug Manufacturers companies, Tibet Rhodiola Pharmaceutical Holding Co ranks better than 73.4% on this metric.

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-21), Tibet Rhodiola Pharmaceutical Holding Co's share price is ¥38.88. Tibet Rhodiola Pharmaceutical Holding Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.00. Therefore, Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) for today is 12.96.

Good Sign:

Tibet Rhodiola Pharmaceutical Holding Co stock PE Ratio (=12.77) is close to 1-year low of 11.87.


The historical rank and industry rank for Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) or its related term are showing as below:

SHSE:600211' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 10.72   Med: 26.22   Max: 79.38
Current: 12.96


During the past 13 years, the highest PE Ratio (TTM) of Tibet Rhodiola Pharmaceutical Holding Co was 79.38. The lowest was 10.72. And the median was 26.22.


SHSE:600211's PE Ratio (TTM) is ranked better than
73.4% of 639 companies
in the Drug Manufacturers industry
Industry Median: 21.04 vs SHSE:600211: 12.96

Tibet Rhodiola Pharmaceutical Holding Co's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was ¥0.93. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.00.

As of today (2026-07-21), Tibet Rhodiola Pharmaceutical Holding Co's share price is ¥38.88. Tibet Rhodiola Pharmaceutical Holding Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.01. Therefore, Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio without NRI for today is 12.92.

During the past 13 years, Tibet Rhodiola Pharmaceutical Holding Co's highest PE Ratio without NRI was 79.07. The lowest was 7.98. And the median was 18.58.

Tibet Rhodiola Pharmaceutical Holding Co's EPS without NRI for the three months ended in Mar. 2026 was ¥0.94. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.01.

During the past 12 months, Tibet Rhodiola Pharmaceutical Holding Co's average EPS without NRI Growth Rate was -5.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 33.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 43.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 22.80% per year.

During the past 13 years, Tibet Rhodiola Pharmaceutical Holding Co's highest 3-Year average EPS without NRI Growth Rate was 133.90% per year. The lowest was -43.20% per year. And the median was 17.05% per year.

Tibet Rhodiola Pharmaceutical Holding Co's EPS (Basic) for the three months ended in Mar. 2026 was ¥0.93. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.00.


Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Tibet Rhodiola Pharmaceutical Holding Co PE Ratio (TTM) Related Terms


Tibet Rhodiola Pharmaceutical Holding Co PE Ratio (TTM) Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co PE Ratio (TTM) Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.35 24.11 15.14 11.33 14.62

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.16 11.92 15.36 14.62 13.53

SHSE:600211 vs ZTS, UTHR: PE Ratio (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Rhodiola Pharmaceutical Holding Co PE Ratio (TTM) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) falls into.


SHSE:600211
94GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
PE Ratio (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=38.88/3.000
=12.96

Tibet Rhodiola Pharmaceutical Holding Co's Share Price of today is ¥38.88.
Tibet Rhodiola Pharmaceutical Holding Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio (TTM) →
What does a PE Ratio (TTM) of 12.96 mean?
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a PE Ratio (TTM) of 12.96 as of Jul. 21, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is 51% below median its historical median of 26.22. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) has ranged from 10.72 to 79.38. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #170 out of 639 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) too high?
Tibet Rhodiola Pharmaceutical Holding Co's current PE Ratio (TTM) of 12.96 is 51% below median its 10-year median of 26.22. Over the past 10 years, this metric has ranged from a low of 10.72 to a high of 79.38. The Drug Manufacturers industry median PE Ratio (TTM) is 21.04. Tibet Rhodiola Pharmaceutical Holding Co's value of 12.96 is 38.4% below this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #170 out of 639 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's PE Ratio (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #170 out of 639 companies for PE Ratio (TTM). This puts Tibet Rhodiola Pharmaceutical Holding Co in the upper half of its industry. The industry median PE Ratio (TTM) is 21.04. Tibet Rhodiola Pharmaceutical Holding Co's value of 12.96 is 38.4% below this benchmark. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own PE Ratio (TTM) has ranged from 10.72 to 79.38 over the past decade. While the company's 10-year median is 26.22 vs. the industry median of 21.04, Tibet Rhodiola Pharmaceutical Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 21.04, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current PE Ratio (TTM) of 12.96 is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 21.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current PE Ratio (TTM) is 12.96, which is 51% below median its own 10-year median of 26.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.64, compared to a current price of ¥38.88 — trading 4.3% below its estimated fair value. The current PE Ratio (TTM) is 12.96, which is 51% below median its 10-year median of 26.22 and 38.4% below the Drug Manufacturers industry median of 21.04. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current PE Ratio (TTM) is 12.96 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥38.88 is trading 4.3% below its estimated GF Value™ of ¥40.64. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • PE Ratio (TTM): 12.96 (51% below median its 10-year median of 26.22)
  • GF Value™: ¥40.64 vs. price of ¥38.88 (4.3% below fair value)
  • GF Score™: 94/100 with 2 warning signs
  • Industry Position: 38.4% below the Drug Manufacturers median (#170 of 639)

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score

Get the complete analysis for SHSE:600211

PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.88
Price
¥40.64
GF Value